Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
PD-L1 expression • EGFR mutation • HER-2 expression • MET amplification • MET exon 14 mutation • KRAS wild-type • BRAF wild-type • NRAS wild-type
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • Bavencio (avelumab) • cyclophosphamide • Rybrevant (amivantamab-vmjw) • fludarabine IV • FT536